Added to YB: 2025-05-15
Pitch date: 2025-05-13
ACOG [bullish]
Alpha Cognition Inc.
+49.58%
current return
Author Info
Anders Research shares equity research primarily focused on micro/small/mid-cap biotechnology. We follow companies with mechanistically differentiated approaches to large market opportunities, with special focus in neuroscience. Sign up for the newsletter.
Company Info
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
Market Cap
$109.9M
Pitch Price
$7.07
Price Target
35.00 (+231%)
Dividend
N/A
Sector
Biotechnology
Category
growth
Alpha Cognition: Launching Well-Differentiated Drug into a large Alzheimer's Market Opportunity
ACOG: Zunveyl nearly eliminates GI/sleep side effects of Alzheimer's AChEIs while maintaining efficacy. Launch targeting LTC vertical (32% of scripts) with experienced 32-rep team. $40-60M revenue potential by 2027 vs $120M market cap. Differentiated from failed antibody therapies in $5.5B underserved market. Risks: disease-modifying therapies, physician adoption. $55M cash runway to profitability.
Read full article (17 min)